Hennion & Walsh Asset Management’s Pacira BioSciences PCRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.16M	Buy	203,520 +48,124	+31%	+$1.14M	0.15%	186
2026 Q1	$3.51M	Buy	155,396 +17,291	+13%	+$384K	0.12%	221
2025 Q4	$3.57M	Buy	138,105 +87,210	+171%	+$2.07M	0.12%	212
2025 Q3	$1.31M	Sell	50,895 -927	-2%	-$22.8K	0.05%	447
2025 Q2	$1.24M	Sell	51,822 -2,394	-4%	-$60.3K	0.05%	440
2025 Q1	$1.35M	Sell	54,216 -2,169	-4%	-$51.9K	0.06%	394
2024 Q4	$1.06M	Buy	56,385 +8,636	+18%	+$152K	0.05%	455
2024 Q3	$719K	Buy	47,749 +12,299	+35%	+$210K	0.03%	530
2024 Q2	$1.01M	Buy	+35,450	New	+$1.01M	0.05%	417
2021 Q4	–	Sell	-22,606	Closed	-$1.27M	–	778
2021 Q3	$1.27M	Sell	22,606 -3,640	-14%	-$210K	0.07%	310
2021 Q2	$1.59M	Buy	26,246 +61	+0.2%	+$3.86K	0.08%	274
2021 Q1	$1.83M	Buy	+26,185	New	+$1.87M	0.11%	247

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hennion & Walsh Asset Management's PCRX Position: Q2 2026 in Review

Hennion & Walsh Asset Management increased its Pacira BioSciences (PCRX) stake by 31% in Q2 2026, buying an estimated $1.14M and bringing the position to 203,520 shares worth $5.16M. The position accounts for 0.15% of the portfolio, ranked #186.

Hennion & Walsh Asset Management first reported a position in PCRX in Q1 2021 and has held it in 12 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Hennion & Walsh Asset Management held 203,520 shares of Pacira BioSciences worth $5.16M as of Q2 2026.
Hennion & Walsh Asset Management bought 48,124 Pacira BioSciences shares in Q2 2026, an estimated $1.14M.
Pacira BioSciences made up 0.15% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #186 holding.
Hennion & Walsh Asset Management first reported a position in Pacira BioSciences in Q1 2021 and has held it in 12 quarters since.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.